Predicting the Unpredictable: Drug-Induced QT Prolongation and Torsades de Pointes

Journal of the American College of Cardiology

Volumn 67, Issue 13, 2016, Pages 1639-1650

  Schwartz, Peter J ^a   Woosley, Raymond L ^b,c  

^a ISTITUTO AUXOLOGICO ITALIANO   (Italy)

^b UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^c AZCERT Inc and NDA Partners LLC   (United States)

Author keywords

clinical decision support; pharmacogenomics; QT interval; sudden death; torsades de pointes

Indexed keywords

AZIMILIDE; AZITHROMYCIN; CISAPRIDE; CLARITHROMYCIN; ERYTHROMYCIN; LEVOFLOXACIN; MACROLIDE; POTASSIUM CHANNEL HERG; QUINIDINE; SOTALOL;

ACCESS TO INFORMATION; CLINICAL DECISION SUPPORT SYSTEM; DRUG FATALITY; DRUG LABELING; DRUG RECALL; DRUG SURVEILLANCE PROGRAM; ELECTRONIC MEDICAL RECORD; FOOD AND DRUG ADMINISTRATION; GENE; GENE MUTATION; HEALTH PROGRAM; HEREDITY; HERG GENE; HUMAN; INTERNATIONAL CLASSIFICATION OF DISEASES; INTERNET; MEDICAL DECISION MAKING; MEDICAL EXPERT; PATHOPHYSIOLOGY; PATIENT CARE; PATIENT MONITORING; PREDICTION; PRESCRIPTION; PRIORITY JOURNAL; QT PROLONGATION; REVIEW; RISK ASSESSMENT; RISK FACTOR; TORSADE DES POINTES; ADVERSE DRUG REACTION; CHEMICALLY INDUCED; ELECTROCARDIOGRAPHY; GENOMICS; LONG QT SYNDROME;

ADVERSE DRUG REACTION REPORTING SYSTEMS; DECISION SUPPORT SYSTEMS, CLINICAL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; ELECTROCARDIOGRAPHY; GENOMICS; HUMANS; INTERNET; LONG QT SYNDROME; RISK FACTORS; TORSADES DE POINTES;

EID: 85008670859     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2015.12.063     Document Type: Review

References (71)

1. 1 Roden, D.M., Drug-induced prolongation of the QT interval. N Engl J Med 350 (2004), 1013–1022.
2. 2 Crotti, L., Schwartz, P.J., Drug-induced long QT syndrome and exome sequencing: Chinese shadows link past and future. J Am Coll Cardiol 63 (2014), 1438–1440.
3. 3 Clark-Kennedy, A.E., Quinidine in the treatment of auricular fibrillation. QJM 16 (1923), 204–235.
4. 4 Selzer, A., Wray, H.W., Quinidine syncope. Paroxysmal ventricular fibrillation occurring during treatment of chronic atrial arrhythmias. Circulation 30 (1964), 17–26.
5. 5 Reynolds, E.W., Vander Ark, C.R., Quinidine syncope and the delayed repolarization syndromes. Mod Concepts Cardiovasc Dis 45 (1976), 117–122.
6. 6 Friedberg, C.K., Diseases of the Heart. 3rd edition, 1966, WB Saunders, Philadelphia.
7. 7 Schwartz, P.J., Moss, A.J., QT interval prolongation. What does it mean?. J Cardiovasc Med 7 (1982), 1317–1330.
8. 8 Schwartz, P.J., Crotti, L., Insolia, R., Long QT syndrome: from genetics to management. Circ Arrhythm Electrophysiol 5 (2012), 868–877.
9. 9 Schwartz, P.J., Ackerman, M.J., The long QT syndrome: a transatlantic clinical approach to diagnosis and therapy. Eur Heart J 34 (2013), 3109–3116.
10. 10 Dessertenne, F., [Ventricular tachycardia with 2 variable opposing foci]. Arch Mal Coeur Vaiss 59 (1966), 263–272.
11. 11 Monahan, B.P., Ferguson, C.L., Killeavy, E.S., et al. Torsades de pointes occurring in association with terfenadine use. JAMA 264 (1990), 2788–2790.
12. 12 McComb, J.M., Campbell, N.P., Cleland, J., Recurrent ventricular tachycardia associated with QT prologation after mitral valve replacement and its association with intravenous administration of erythromycin. Am J Cardiol 54 (1984), 922–923.
13. 13 Kornick, C.A., Kilborn, M.J., Santiago-Palma, J., et al. QTc interval prolongation associated with intravenous methadone. Pain 105 (2003), 499–506.
14. 14 Ninan, B., Wertheimer, A., Withdrawing drugs in the U.S. versus other countries. Inov Pharm 3 (2012), 1–12.
15. 15 Shah, R.R., Drugs, QTc interval prolongation and final ICH E14 guideline: an important milestone with challenges ahead. Drug Saf 28 (2005), 1009–1028.
16. 16 Woosley, R.L., Romero, K., Assessing cardiovascular drug safety for clinical decision-making. Nat Rev Cardiol 10 (2013), 330–337.
17. 17 Drew, B.J., Ackerman, M.J., Funk, M., et al. Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation endorsed by the American Association of Critical-Care Nurses and the International Society for Computerized Electrocardiology. J Am Coll Cardiol 55 (2010), 934–947.
18. 18 Yan, G.X., Antzelevitch, C., Cellular basis for the normal T wave and the electrocardiographic manifestations of the long-QT syndrome. Circulation 98 (1998), 1928–1936.
19. 19 Jackman, W.M., Friday, K.J., Anderson, J.L., et al. The long QT syndromes: a critical review, new clinical observations and a unifying hypothesis. Prog Cardiovasc Dis 31 (1988), 115–172.
20. 20 Han, J., Moe, G.K., Nonuniform recovery of excitability in ventricular muscle. Circ Res 14 (1964), 44–60.
21. Kr block is insufficient to detect torsades de pointes liability: role of late sodium current. Circulation 130 (2014), 224–234.
22. 22 Schwartz, P.J., Wolf, S., QT interval prolongation as predictor of sudden death in patients with myocardial infarction. Circulation 57 (1978), 1074–1077.
23. 23 Straus, S.M., Kors, J.A., De Bruin, M.L., et al. Prolonged QTc interval and risk of sudden cardiac death in a population of older adults. J Am Coll Cardiol 47 (2006), 362–367.
24. 24 Niemeijer, M.N., van den Berg, M.E., Deckers, J.W., et al. Consistency of heart rate-QTc prolongation consistency and sudden cardiac death: The Rotterdam Study. Heart Rhythm 12 (2015), 2078–2085.
25. 25 Ray, W.A., Murray, K.T., Hall, K., et al. Azithromycin and the risk of cardiovascular death. N Engl J Med 366 (2012), 1881–1890.
26. 26 Ray, W.A., Chung, C.P., Murray, K.T., et al. Out-of-hospital mortality among patients receiving methadone for noncancer pain. JAMA Intern Med 175 (2015), 420–427.
27. 27 Ray, W.A., Murray, K.T., Meredith, S., et al. Oral erythromycin and the risk of sudden death from cardiac causes. N Engl J Med 351 (2004), 1089–1096.
28. 28 Holmgren, C.M., Abdon, N.J., Bergfeldt, L.B., et al. Changes in medication preceding out-of-hospital cardiac arrest where resuscitation was attempted. J Cardiovasc Pharmacol 63 (2014), 497–503.
29. 29 Leonard, C.E., Freeman, C.P., Newcomb, C.W., et al. Antipsychotics and the risks of sudden cardiac death and all-cause death: cohort studies in Medicaid and dually-eligible Medicaid-Medicare beneficiaries of five states. J Clin Exp Cardiol(Suppl 10), 2013, 1–9.
30. 30 Zeltser, D., Justo, D., Halkin, A., et al. Torsade de pointes due to noncardiac drugs: most patients have easily identifiable risk factors. Medicine (Baltimore) 82 (2003), 282–290.
31. 31 Romero, K., Woosley, R.L., Clarification to the www.qtdrugs.org updated lists. Pharmacoepidemiol Drug Saf 18 (2009), 423–424.
32. 32 Woosley RL, Romero KA. Crediblemeds.org QT drugs List, 2016. AZCERT, Inc. Available at: https://crediblemeds.org. Accessed January 22, 2016.
33. 33 AZCERT, Inc. Adverse drug event causality analysis (ADECA). Available at: https://www.crediblemeds.org/research-scientists/why-lists/. Accessed January 22, 2016.
34. 34 Postema, P.G., Neville, J., de Jong, J.S., et al. Safe drug use in long QT syndrome and Brugada syndrome: comparison of website statistics. Europace 15 (2013), 1042–1049.
35. 35 Hill, A.B., The environment and disease: association or causation?. Proc R Soc Med 58 (1965), 295–300.
36. 36 Sarganas, G., Garbe, E., Klimpel, A., et al. Epidemiology of symptomatic drug-induced long QT syndrome and Torsade de Pointes in Germany. Europace 16 (2014), 101–108.
37. 37 Cheng, Y.J., Nie, X.Y., Chen, X.M., et al. The role of macrolide antibiotics in increasing cardiovascular risk. J Am Coll Cardiol 66 (2015), 2173–2184.
38. 38 Kay, G.N., Plumb, V.J., Arciniegas, J.G., et al. Torsades de pointes: the long-short initiating sequence and other clinical features: observations in 32 patients. J Am Coll Cardiol 2 (1983), 806–817.
39. 39 Roden, D.M., Woosley, R.L., Primm, R.K., Incidence and clinical features of the quinidine-associated long-QT syndrome: implications for patient care. Am Heart J 111 (1986), 1088–1093.
40. 40 Pratt, C.M., Al-Khalidi, H.R., Brum, J.M., et al., for the Azimilide Trials Investigators. Cumulative experience of azimilide-associated torsades de pointes ventricular tachycardia in the 19 clinical studies comprising the azimilide database. J Am Coll Cardiol 48 (2006), 471–477.
41. 41 Molokhia, M., Pathak, A., Lapeyre-Mestre, M., Caturla, L., et al. Case ascertainment and estimated incidence of drug-induced long-QT syndrome: study in southwest France. Br J Clin Pharmacol 66 (2008), 386–395.
42. 42 Pearson, E.C., Woosley, R.L., QT prolongation and torsades de pointes among methadone users: reports to the FDA spontaneous reporting system. Pharmacoepidemiol Drug Saf 14 (2005), 747–753.
43. 43 Woosley, R.L., Chen, Y., Freiman, J.P., et al. Mechanism of the cardiotoxic actions of terfenadine. JAMA 269 (1993), 1532–1536.
44. 44 Hennessy, S., Bilker, W.B., Knauss, J.S., et al. Cardiac arrest and ventricular arrhythmia in patients taking antipsychotic drugs: cohort study using administrative data. BMJ, 325, 2002, 1070.
45. 45 Straus, S.M., Sturkenboom, M.C., Bleumink, G.S., et al. Non-cardiac QTc-prolonging drugs and the risk of sudden cardiac death. Eur Heart J 26 (2005), 2007–2012.
46. 46 Rao, G.A., Mann, J.R., Shoaibi, A., et al. Azithromycin and levofloxacin use and increased risk of cardiac arrhythmia and death. Ann Fam Med 12 (2014), 121–127.
47. 47 Mosholder, A.D., Mathew, J., Alexander, J.J., et al. Cardiovascular risks with azithromycin and other antibacterial drugs. N Engl J Med 368 (2013), 1665–1668.
48. 48 Svanström, H., Pasternak, B., Hviid, A., Use of clarithromycin and roxithromycin and risk of cardiac death: cohort study. BMJ, 349, 2014, g4930.
49. 49 Haugaa, K.H., Bos, J.M., Tarrell, R.F., et al. Institution-wide QT alert system identifies patients with a high risk of mortality. Mayo Clin Proc 88 (2013), 315–325.
50. 50 Sorita, A., Bos, J.M., Morlan, B.W., et al. Impact of clinical decision support preventing the use of QT-prolonging medications for patients at risk for torsade de pointes. J Am Med Inform Assoc 22 (2015), e21–e27.
51. 51 Tisdale, J.E., Jaynes, H.A., Kingery, J.R., et al. Development and validation of a risk score to predict QT interval prolongation in hospitalized patients. Circ Cardiovasc Qual Outcomes 6 (2013), 479–487.
52. 52 Tisdale, J.E., Jaynes, H.A., Kingery, J.R., et al. Effectiveness of a clinical decision support system for reducing the risk of QT interval prolongation in hospitalized patients. Circ Cardiovasc Qual Outcomes 7 (2014), 381–390.
53. 53 Redfern, W.S., Carlsson, L., Davis, A.S., et al. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res 58 (2003), 32–45.
54. 54 Kongsamut, S., Kang, J., Chen, X.L., et al. A comparison of the receptor binding and HERG channel affinities for a series of antipsychotic drugs. Eur J Pharmacol 450 (2002), 37–41.
55. 55 Soyka, L.F., Wirtz, C., Spangenberg, R.B., Clinical safety profile of sotalol in patients with arrhythmias. Am J Cardiol 65 (1990), 74A–81A discussion 82A–83A.
56. 56 Meyer-Massetti, C., Cheng, C.M., Sharpe, B.A., et al. The FDA extended warning for intravenous haloperidol and torsades de pointes: how should institutions respond?. J Hosp Med 5 (2010), E8–E16.
57. 57 Hancox, J.C., Hasnain, M., Vieweg, W.V., et al. Erythromycin, QTc interval prolongation, and torsade de pointes: case reports, major risk factors and illness severity. Ther Adv Infect Dis 2 (2014), 47–59.
58. 58 Schwartz, P.J., Ackerman, M.J., George, A.L. Jr., et al. Impact of genetics on the clinical management of channelopathies. J Am Coll Cardiol 62 (2013), 169–180.
59. 59 Napolitano, C., Schwartz, P.J., Brown, A.M., et al. Evidence for a cardiac ion channel mutation underlying drug-induced QT prolongation and life-threatening arrhythmias. J Cardiovasc Electrophysiol 11 (2000), 691–696.
60. 60 Yang, P., Kanki, H., Drolet, B., et al. Allelic variants in long QT disease genes in patients with drug-associated torsades de pointes. Circulation 105 (2002), 1943–1948.
61. 61 Kääb, S., Crawford, D.C., Sinner, M.F., et al. A large candidate gene survey identifies the KCNE1 D85N polymorphism as a possible modulator of drug-induced torsades de pointes. Circ Cardiovasc Genet 5 (2012), 91–99.
62. 62 Behr, E.R., Ritchie, M.D., Tanaka, T., et al. Genome wide analysis of drug-induced torsades de pointes: lack of common variants with large effect sizes. PLoS One, 8, 2013, e78511.
63. 63 Ramirez, A.H., Shaffer, C.M., Delaney, J.T., et al. Novel rare variants in congenital cardiac arrhythmia genes are frequent in drug-induced torsades de pointes. Pharmacogenomics J 13 (2013), 325–329.
64. 64 Weeke, P., Mosley, J.D., Hanna, D., et al. Exome sequencing implicates an increased burden of rare potassium channel variants in the risk of drug induced long QT interval syndrome. J Am Coll Cardiol 63 (2014), 1430–1437.
65. 65 Itoh, H., Crotti, L., Aiba, T., et al. The genetics underlying acquired long QT syndrome: impact for genetic screening. Eur Heart J, 2015 Dec 28 [E-pub ahead of print].
66. 66 Niemeijer, M.N., van den Berg, M.E., Eijgelsheim, M., et al. Pharmacogenetics of drug-induced QT interval prolongation: an update. Drug Saf 38 (2015), 855–867.
67. 67 Tamblyn, R., Eguale, T., Buckeridge, D.L., et al. The effectiveness of a new generation of computerized drug alerts in reducing the risk of injury from drug side effects: a cluster randomized trial. J Am Med Inform Assoc 19 (2012), 635–643.
68. 68 Seidling, H.M., Klein, U., Schaier, M., et al. What, if all alerts were specific: estimating the potential impact on drug interaction alert burden. Int J Med Inform 83 (2014), 285–291.
69. 69 Bryant, A.D., Fletcher, G.S., Payne, T.H., Drug interaction alert override rates in the Meaningful Use era: no evidence of progress. Appl Clin Inform 5 (2014), 802–813.
70. 70 Payne, T.H., Hines, L.E., Chan, R.C., et al. Recommendations to improve the usability of drug-drug interaction clinical decision support alerts. J Am Med Inform Assoc 22 (2015), 1243–1250.
71. 71 Woosley, R.L., Whyte, J., Mohamadi, A., et al. Medical decision support systems and therapeutics: the role of autopilots. Clin Pharmacol Ther 99 (2016), 161–164.